Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $79.80 USD
Change Today +2.16 / 2.78%
Volume 381.0K
LGND On Other Exchanges
Symbol
Exchange
NASDAQ GM
OTC US
Frankfurt
OTC US
OTC US
OTC US
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals (LGND) Key Developments

Ligand Pharmaceuticals Incorporated Announces Management Changes

Ligand Pharmaceuticals Incorporated announced the appointment of Melanie J. Herman as interim Chief Financial Officer, effective May 21, 2015. Ms. Herman currently serves as Ligand’s Director of Accounting and Chief Accounting Officer. She succeeds Nishan de Silva, who has accepted the position of President and Chief Operating Officer at a privately held therapeutics-focused gene editing company and who has notified Ligand of his resignation, to be effective next month. Ms. Herman joined Ligand in January 2011 as the company’s Controller, and was named Director of Accounting in March 2014 and Chief Accounting Officer in April 2014. Previously she was Controller at CyDex Pharmaceuticals Inc. from 2009 to 2011, Assistant Controller and Accounting Manager at Entertainment Properties Trust from 2004 to 2009 and Senior Accountant at KPMG, LLP from 2001 to 2004.

Ligand Pharmaceuticals Incorporated Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015

Ligand Pharmaceuticals Incorporated Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015 . Venue: JW Marriott Denver at Cherry Creek, 150 Clayton Lane, Denver, CO 80206, United States.

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Apr 24, 2015

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Apr 24, 2015., at 08:30 Pacific Daylight. Location: 11119 North Torrey Pines Road. Agenda: To elect a board of directors for the forthcoming year; to ratify the selection of Grant Thornton LLP as the company's independent registered accounting firm for the fiscal year ending December 31, 2015; to consider and vote upon, on an advisory basis, the compensation of its named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and to transact such other business as may properly come before the meeting or any adjournment(s) thereof.

Ligand Pharmaceuticals Incorporated Presents at 27th Annual ROTH Conference, Mar-09-2015 02:30 PM

Ligand Pharmaceuticals Incorporated Presents at 27th Annual ROTH Conference, Mar-09-2015 02:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: John L. Higgins, Chief Executive Officer and Executive Director.

Ligand Pharmaceuticals Incorporated Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter and Full Year of 2015

Ligand Pharmaceuticals Incorporated reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. Total revenues for the fourth quarter of 2014 were $23.0 million, an increase of 56% compared with $14.7 million for the same period in 2013. Net income was $7.1 million, or $0.34 per diluted share, compared with net income for the fourth quarter of 2013 of $1.9 million, or $0.09 per diluted share. Non-GAAP net income from continuing operations for the fourth quarter of 2014 was $12.5 million, or $0.60 per diluted share, compared with non-GAAP net income from continuing operations for the fourth quarter of 2013 of $7.5 million, or $0.35 per diluted share. Total revenues for 2014 increased 32% to $64.5 million compared with $49.0 million for 2013. Net income from continuing operations for 2014 was $12.0 million, or $0.56 per diluted share, compared with net income from continuing operations of $8.8 million, or $0.43 per share, for 2013. Non-GAAP net income from continuing operations for 2014 was $32.6 million, or $1.52 per diluted share, compared with $19.0 million, or $0.92 per diluted share, for 2013. Net income was $12.02 million, or $0.56 per diluted share, compared with net income of $11.42 million, or $0.43 per diluted share. For the first quarter of 2015, the company expects total revenues to be between $13.0 million and $13.5 million and non-GAAP earnings per diluted share to be between $0.25 and $0.27. The non-GAAP earnings per diluted share guidance does not include changes in contingent liabilities, mark-to-market adjustment for amounts owed to licensors, non-cash stock based compensation expense and non-cash debt related costs. Affirming its previous full-year 2015 financial forecast, the company expects total revenues to be between $81.0 million and $83.0 million, and non-GAAP earnings per diluted share to be between $2.14 and $2.18. The company expects that approximately half of 2015 revenue will be derived from royalties.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGND:US $79.80 USD +2.16

LGND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LGND.
View Industry Companies
 

Industry Analysis

LGND

Industry Average

Valuation LGND Industry Range
Price/Earnings 100.0x
Price/Sales 24.6x
Price/Book 59.4x
Price/Cash Flow 130.3x
TEV/Sales 18.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.